MOTS-c vs Tirzepatide
A side-by-side research comparison of MOTS-c and Tirzepatide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | MOTS-c | Tirzepatide |
|---|---|---|
| Full name | Mitochondrial Open Reading Frame of the 12S rRNA-c | Tirzepatide (Dual GIP/GLP-1 Receptor Agonist) |
| Category | Weight Management | Weight Management |
| Status | Research compound | FDA Approved |
| Mechanism | Activates AMPK pathway, enhances mitochondrial metabolism, improves insulin sensitivity by increasing GLUT4 translocation, and promotes fatty acid oxidation. | Activates both GIP and GLP-1 receptors simultaneously for synergistic effects on insulin secretion, appetite reduction, and fat metabolism. GIP activation enhances fat oxidation and energy expenditure. |
| Molecular weight | 2,175 Da | 4,814 Da |
| Half-life | 4-8 hours | 5 days (120 hours) |
| Bioavailability | Moderate (SubQ) | High (SubQ ~80%) |
| Typical dose | 5-10 mg | 2.5 mg → titrate up to 15 mg |
| Frequency | 3-5x per week | Once weekly |
| Route | Subcutaneous injection | Subcutaneous injection |
MOTS-c reported benefits
- Exercise mimetic effects
- Improved insulin sensitivity
- Enhanced fat oxidation
- Metabolic homeostasis
- Anti-aging metabolic benefits
- AMPK activation
Tirzepatide reported benefits
- Superior weight loss (20-25%)
- Excellent glycemic control
- Reduced triglycerides
- Lower blood pressure
- Improved insulin sensitivity
- Potential MASH benefits
Related comparisons
Research and educational reference only. Not medical advice.